One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...

Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...

BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks (DNA) reported strong Q3 results driven by $45M in released deferred revenues from the terminated contract with Motif, and cost ...

Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, ...

Q3 2024 Earnings Call Transcript November 12, 2024 Megan LeDuc: Good evening. I’m Megan LeDuc, Manager of Investor Relations ...

Revenue: US$89.0m (up 61% from 3Q 2023). Net loss: US$56.4m (loss narrowed by 81% from 3Q 2023). US$1.08 loss per share (improved from US$6.21 loss in 3Q 2023). Revenue exceeded analyst estimates ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...